Michelle Detwiler

helle Dipp is a Co-Founder and Managing Partner at Biospring Partners.
Michelle has over a decade of healthcare private equity and venture capital expertise.
She currently serves on the Board of Directors of two Biospring portfolio companies, Abzena and Kiniciti.
Michelle was previously a Managing Director at General Atlantic where she launched the firm’s first life sciences investment platform.
At General Atlantic, Michelle led multiple investments including Ginkgo BioWorks (NYSE: DNA), Motif FoodWorks, PathAI, Immunocore (NASDAQ: IMCR) and Ocumension (HK: 1477).
Prior to General Atlantic, Michelle was Co-Founder and General Partner of Longwood Fund, a leading healthcare investment firm based in Boston.
Prior to Longwood, Michelle was the Senior Vice President of the CEEDD at GlaxoSmithKline (NASDAQ: GSK), leading global business development and M&A.
Michelle holds a Bachelor of Medicine and Bachelor of Surgery from the University of Oxford Medical School and a Doctor of Philosophy in Human Physiology from the University of Oxford.
Born and raised in El Paso, Texas, Michelle is passionate about education and healthcare in underserved populations.
Michelle serves on the following Boards: Board of Directors, Women’s Foundation of Boston, focused on underprivileged women and girls Board of Trustees, Xavier University of Louisiana Trustee Advisory Board, Beth Israel Deaconess Medical Center Board of Directors, Life Science Cares, focused on alleviating poverty